1. Home
  2. TSHA vs CCS Comparison

TSHA vs CCS Comparison

Compare TSHA & CCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$6.22

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Century Communities Inc.

CCS

Century Communities Inc.

HOLD

Current Price

$59.11

Market Cap

1.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSHA
CCS
Founded
2019
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
TSHA
CCS
Price
$6.22
$59.11
Analyst Decision
Strong Buy
Buy
Analyst Count
9
5
Target Price
$11.11
$67.00
AVG Volume (30 Days)
2.7M
197.6K
Earning Date
05-14-2026
04-22-2026
Dividend Yield
N/A
2.17%
EPS Growth
5.56
N/A
EPS
N/A
0.84
Revenue
$9,773,000.00
$4,117,816,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$1,152.42
$10.84
P/E Ratio
N/A
$69.95
Revenue Growth
17.28
N/A
52 Week Low
$1.78
$50.42
52 Week High
$6.76
$76.00

Technical Indicators

Market Signals
Indicator
TSHA
CCS
Relative Strength Index (RSI) 63.56 46.64
Support Level $4.24 $56.16
Resistance Level N/A $66.44
Average True Range (ATR) 0.44 2.04
MACD 0.10 0.03
Stochastic Oscillator 78.76 36.77

Price Performance

Historical Comparison
TSHA
CCS

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

About CCS Century Communities Inc.

Century Communities Inc is engaged in the development, design, construction, marketing and sale of single-family attached and detached homes. The company builds and sells homes under its Century Communities and Century Complete brands. Its reportable segments for homebuilding operations are: i) West (California and Washington) ii) Mountain (Arizona, Colorado, Nevada and Utah), iii) Texas, iv) Southeast (Florida, Georgia, North Carolina, South Carolina and Tennessee), v) Century Complete (Alabama, Arizona, Florida, Georgia, Indiana, Kentucky, Michigan, North Carolina, and South Carolina). The company's other reportable segments include: Financial Services and Century Living. The company derives the majority of its revenue from the sale of new homes in the Mountain segment.

Share on Social Networks: